Epigenetic Strategies to Boost Cancer Immunotherapies

Recently, immunotherapeutic approaches have shown impressive responses in a subset of cancer patients. However, the rate of success is low and a large percentage of treated patients do not experience clinical benefits. Therefore, additional strategies are needed to improve responses and select respo...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of molecular sciences Vol. 18; no. 6; p. 1108
Main Author Barrero, Maria J
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 23.05.2017
MDPI
Subjects
cancer
Cancer immunotherapy
Cancer therapies
DNA methylation
Drugs
Epigenesis, Genetic - genetics
Epigenetics
Humans
Immunosuppressive agents
Immunotherapy
Immunotherapy - methods
Kinases
Neoplasms - genetics
Neoplasms - therapy
Patients
Review
cancer
epigenetics
immunotherapy
Online AccessGet full text

Cover

More Information
Summary:Recently, immunotherapeutic approaches have shown impressive responses in a subset of cancer patients. However, the rate of success is low and a large percentage of treated patients do not experience clinical benefits. Therefore, additional strategies are needed to improve responses and select responsive patients. Emerging data suggest that epigenetic drugs can improve the responses to immunotherapy. Understanding the mechanisms of resistance to immunotherapy and the epigenetic events that take place during immune evasion is critical to providing a rational combined use of immunotherapies and epigenetic drugs. This review focuses in the epigenetic mechanisms involved in the responses to immunotherapy and how current drugs that target epigenetic regulators impact on them.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms18061108